Publications

Filter results by

Filtered by:

Charu Aggarwal

List of Publications

Title Date PC3I Authors Journal
Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer August 31, 2023
PC3I Authors
Michelle Iocolano; Catherine Lai; Charu Aggarwal; Melina Marmarelis
International Journal of Radiation Oncology, Biology, Physics
Impact of Interobserver Variability in Manual Segmentation of Non-Small Cell Lung Cancer (NSCLC) Applying Low-Rank Radiomic Representation on Computed Tomography December 10, 2021
PC3I Authors
Charu Aggarwal
Cancers
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors October 3, 2023
PC3I Authors
Charu Aggarwal; Dylan G. Scholes
British Journal of Cancer
Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy January 30, 2022
PC3I Authors
Melina Marmarelis; Ronac Mamtani; Charu Aggarwal
Clinical Lung Cancer
Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression October 9, 2023
PC3I Authors
Michelle Iocolano; Charu Aggarwal; Melina Marmarelis; Christopher A. D’Avella
Clinical Lung Cancer
A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers March 4, 2022
PC3I Authors
Charu Aggarwal
Oral Oncology
Patterns of Failure, Low-Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors October 22, 2023
PC3I Authors
Michelle Iocolano; Charu Aggarwal; Melina Marmarelis
International Journal of Radiation Oncology, Biology, Physics
Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot Study April 8, 2022
PC3I Authors
Charu Aggarwal; Melina Marmarelis; Christopher A. D’Avella; Anil Vachani
JTO Clinical and Research Reports
The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC November 26, 2023
PC3I Authors
Michelle Iocolano; Charu Aggarwal
Radiotherapy and Oncology
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed April 8, 2022
PC3I Authors
Charu Aggarwal; Melina Marmarelis; Christopher A. D’Avella
Clinical Lung Cancer
Concurrent Circulating Tumor DNA and Tissue Genotyping-Ready for Prime Time? January 22, 2024
PC3I Authors
Charu Aggarwal
JAMA Network Open
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial April 13, 2022
PC3I Authors
Charu Aggarwal
Journal for Immunotherapy of Cancer
Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era January 31, 2024
PC3I Authors
Michelle Iocolano; Charu Aggarwal
Cancer
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer April 22, 2022
PC3I Authors
Charu Aggarwal
Journal of Clinical Oncology
Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels March 3, 2024
PC3I Authors
Charu Aggarwal
Lung Cancer (Amsterdam, Netherlands)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma May 31, 2022
PC3I Authors
Charu Aggarwal
Journal for Immunotherapy of Cancer
Aumolertinib in EGFR-Mutant Lung Cancer: Will the Promise of Cost Disruption Ease Access? June 9, 2022
PC3I Authors
Charu Aggarwal
Journal of Clinical Oncology
Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy June 15, 2022
PC3I Authors
Charu Aggarwal
Scientific Reports
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors August 11, 2022
PC3I Authors
Charu Aggarwal
JCO Precision Oncology
Prevalence of ARID1A Mutations in Cell-Free Circulating Tumor DNA in a Cohort of 71,301 Patients and Association with Driver Co-Alterations September 9, 2022
PC3I Authors
Charu Aggarwal
Cancers (Basel)